Drug firm Zydus Lifesciences Ltd on Friday (October 24) said it has received a Notice of Compliance (NOC) from Health Canada for its generic Mesalamine suppositories 1000 mg. The product is indicated for the treatment of mildly to moderately active ulcerative proctitis.

The Mesalamine suppositories will be manufactured at Zydus Lifesciences’ facility in Changodar, Ahmedabad, Gujarat. In Canada, Mesalamine suppositories had annual sales of 4.86 million CAD as per IQVIA MAT data for June 2025.

This month, Zydus Lifesciences said it had received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths.

Also Read: Zydus Lifesciences arm launches generic drugs for cats and dogs in US

Liothyronine, a synthetic form of the thyroid h

See Full Page